Caribou Biosciences’ CB-011 Granted Fast Track Designation by FDA for Relapsed or Refractory Multiple Myeloma
Caribou Biosciences Ltd., a top-notch clinical-stage biopharmaceutical company specializing in CRISPR genome-editing, has recently received Fast Track designation from the U.S. Food and Drug Administr ...